Contact
      Please use this form to send email to PR contact of this press release:
      
      Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints
    
      TO:
      
      
      
      
      
      
      
    
      Please use this form to send email to PR contact of this press release:
      
      Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints
    
      TO: